Similarly, as we learn more about how GLP-1 RAs protect against atherosclerosis and CVD with trials such as SELECT [91], we will need to consider how management of ASCVD with these agents fits within this wider issue of equitable access and the effects of withdrawal of treatments, which can result in weight regain and reversal of cardiometabolic benefits [164]. Here, GLP1R is linked to atherosclerosis.